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MaOBJECTIVES This study sought to report the 5-year outcomes of everolimus-eluting stents (EES) and paclitaxel-eluting
stents (PES) in an all-comers population undergoing percutaneous coronary intervention (PCI).
BACKGROUND The medium-term 1 and 2-year results of the prospective randomized COMPARE trial (A Trial of
Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) showed superior
clinical outcomes with EES compared with PES in an all-comers PCI population. Whether this beneﬁt is sustained over
longer-term follow-up is unknown. Furthermore, systematic long-term follow-up data on these metallic drug eluting
stents with durable polymers are scarce.
METHODS We randomly assigned 1,800 patients undergoing PCI to EES or PES. The pre-speciﬁed composite primary
endpoint was death, myocardial infarction (MI), or target vessel revascularization (TVR).
RESULTS Follow-up at 5 years was completed in 1,791 (99.5%) patients. Treatment with EES compared with PES led to
a relative risk reduction of the primary endpoint by 27% (18.4% vs. 25.1%, p ¼ 0.0005), driven by lower rates of MI
(7.0% vs. 11.5%, p ¼ 0.001) and TVR (7.4% vs. 11.4%, p ¼ 0.003), but not with mortality (9.0% vs. 10.3%, relative risk
0.88, p ¼ 0.36). Moreover, patients treated with EES compared with PES had lower rates of deﬁnite/probable stent
thrombosis at 5 years (3.1% vs. 5.9%, p ¼ 0.005). The hazard curves for TVR, MI, and stent thrombosis diverge over the
ﬁrst 3 years and, subsequently, progress in parallel.
CONCLUSIONS The early- and medium-term superiority of EES over PES measured both by safety and efﬁcacy
endpoints is sustained at 5 years in this all-comer population. (A Trial of Everolimus-Eluting Stents and Paclitaxel-
Eluting Stents for Coronary Revascularization in Daily Practice [COMPARE]; NCT01016041) (J Am Coll Cardiol Intv
2015;8:1157–65) © 2015 by the American College of Cardiology Foundation.T he introduction of drug-eluting stents (DES)signiﬁcantly reduced restenosis after percuta-neous coronary interventions (PCI), thereby
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TABLE 1 Baseline Patient and L
Age, median, yrs
Men
Diabetes mellitus*
Chronic renal failure†
Hypertension
Hypercholesterolemia
Current smoker
Family history of CAD
History of myocardial infarction
History of percutaneous coronary
History of coronary artery bypass
Stable angina pectoris
Acute coronary syndrome
Unstable angina
Non–ST-segment elevation myoca
infarction
ST-segment elevation myocardial
Multivessel treatment
Treated lesions per patient, n  SD
Lesion length $20 mm
Number of lesions
Number of stents per lesion, mean
Total stent length per lesion, med
Direct stenting
Type B2 or C lesion
Bifurcation lesion
Thrombus present
Chronic total occlusion
Values are n (%) except as noted. *Diabe
diabetes. †Chronic renal failure was deﬁ
CAD ¼ coronary artery disease.
ABBR EV I A T I ON S
AND ACRONYMS
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
PES = paclitaxel-eluting
stent(s)
RRR = relative risk reduction
ST = stent thrombosis
TLR = target lesion
revascularization
TVR = target vessel
revascularization
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1158beneﬁt (2). Newer-generation DES were
designed to improve both the efﬁcacy and
safety proﬁle. Several studies showed that
the newer-generation everolimus-eluting
stent (EES) XIENCE-V (Abbott Vascular, Santa
Clara, California) was superior to the ﬁrst-
generation paclitaxel-eluting stent (PES)
TAXUS EXPRESS2 (Boston Scientiﬁc, Natick,
Massachusetts) (3–5). However, as a result of
strict inclusion and exclusion criteria, mainly
low-risk patient and lesion characteristics
were studied, thereby making extrapolation
of these conclusions to real-life practice prob-
lematic. Furthermore, follow-up was gener-
ally limited to 3 years (6), and recent data
suggest that longer follow-up of 5 years or
more is needed to truly evaluate the effect of
different DES. In 3 recently reported compara-tive stent trials, the results and conclusions at 1 year
differed from those at 4- and 5-year follow-up (7–9).esion Characteristics
Everolimus-Eluting
Stent
(n ¼ 897)
Paclitaxel-Eluting
Stent
(n ¼ 903)
62.9 63.6
619 (69) 654 (72)
153 (17) 172 (19)
25 (3) 24 (3)
417 (46) 447 (50)
477 (53) 451 (50)
295 (33) 262 (29)
399 (44) 403 (45)
136 (15) 159 (18)
intervention 117 (13) 123 (14)
surgery 60 (7) 53 (6)
331 (37) 349 (39)
541 (60) 534 (59)
107 (12) 105 (12)
rdial 194 (22) 217 (24)
infarction 240 (27) 212 (23)
244 (27) 239 (26)
1.4  0.7 1.4  0.7
290 (32) 263 (29)
1,286 1,294
 SD 1.7  0.9 1.6  0.9
ian (IQR) 28 (18–46) 28 (18–44)
432 (34) 451 (35)
950 (74) 955 (74)
223 (17) 237 (18)
310 (3) 314 (24)
39 (3) 53 (4)
tes was deﬁned as treatment by diet or drugs for previously diagnosed
ned as serum creatinine of >130 mmol/l or on dialysis.The prospective randomized COMPARE trial (A Trial
of Everolimus-Eluting Stents and Paclitaxel-Eluting
Stents for Coronary Revascularization in Daily Prac-
tice) was an investigator-initiated all-comers study
designed to compare the second-generation PES
TAXUS LIBERTÉ with the second-generation EES
XIENCE-V in real-life practice. The results at 1 year
showed superiority of EES over PES with regard to
both efﬁcacy and safety endpoints, driven by lower
rates of myocardial infarction (MI), ST and target
vessel revascularization (TVR) (10). These clinical
beneﬁts of EES over PES were maintained at 2 years,
driven by lower rates of ST and TVR (11). Whether the
documented beneﬁt of EES is maintained at later
follow-up has not been addressed. Therefore, we
report the ﬁnal 5-year results of the COMPARE trial.
METHODS
The study design has been reported elsewhere (10).
Brieﬂy, the COMPARE trial was a prospective, ran-
domized, single-blinded, single-center trial com-
paring PES (TAXUS LIBERTÉ) and EES (XIENCE-V).
Consecutive patients aged 18 years or older referred to
Maasstad Ziekenhuis, Rotterdam, the Netherlands, for
elective or emergent percutaneous coronary inter-
vention were eligible for enrollment. Major exclusion
criteria were contraindications to dual antiplatelet
therapy (DAPT) or planned major surgery within
30 days necessitating DAPT interruption. The study
was approved by the institutional ethics committee of
theMaasstad Ziekenhuis, Rotterdam, the Netherlands,
and registered in the Dutch Central Committee
on Research Involving Human Subjects (CCMO
trial no. NL15206.101.06) and in ClinicalTrials.gov
(NCT01016041). All patients provided written in-
formed consent.
PCI was performed according to standard tech-
niques, and patients were assigned on a 1:1 basis to
EES or PES. Procedural details, including pre-and
periprocedural pharmacotherapy, have been previ-
ously reported (10). Patients were discharged from
hospital on aspirin 100 mg daily indeﬁnitely and
clopidogrel 75 mg daily for 12 months.
Clinical follow-up was performed at hospital
discharge and at 1, 6, and 12 months. Study monitors
collected data by visits, phone calls, and postal
questionnaires annually up to 5 years. Reported
adverse events and hospitalizations were monitored.
Data processing and adjudication of adverse events
were done in a blinded fashion by an independent
core laboratory and the Clinical Events Committee
masked to treatment assignment (Cardialysis, Rot-
terdam, the Netherlands).
FIGURE 1 Study Flow Chart
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1159The pre-speciﬁed patient-oriented primary end-
point of the COMPARE trial was a composite of death,
nonfatal MI, and TVR at 5 years. The secondary
device-speciﬁc endpoint was a composite of major
adverse cardiac events (cardiac death, nonfatal MI,
and clinically driven target lesion revascularization
[TLR]). Deﬁnition of endpoints are presented else-
where (10).
STATISTICAL ANALYSIS. All analyses were per-
formed by intention to treat. Categorical outcomes
were compared with the chi-square test or Fisher
exact test, and continuous variables with the Wil-
coxon rank sum test. The time to the endpoints was
assessed according to the method of Kaplan-Meier,
and the log-rank test. Relative risk with 95% conﬁ-
dence intervals were calculated using the normal
approximation to the binomial distribution. All p
values were 2-sided, and a p value <0.05 was
considered to indicate statistical signiﬁcance. Ana-
lyses were performed using SAS version 8.02 (SAS
Institute, Cary, North Carolina).TABLE 2 Events at 5 Years
Events
EES
(n ¼ 897)
PES
(n ¼ 903)
RR
(EES/PES)
Lower
Limit RR
Upper
Limit RR p Value
Death 81 (9.0) 93 (10.3) 0.88 0.66 1.16 0.36
Cardiac death 40 (4.5) 42 (4.7) 0.96 0.63 1.46 0.85
MI 63 (7.0) 104 (11.5) 0.61 0.45 0.82 <0.01
Q-wave 19 (2.1) 23 (2.5) 0.83 0.46 0.82 <0.01
Non–Q-wave 44 (4.9) 85 (9.4) 0.52 0.37 0.74 <0.01
Death or MI 131 (14.6) 182 (20.2) 0.72 0.59 0.88 <0.01
Cardiac death or MI 92 (10.3) 135 (15.0) 0.69 0.54 0.88 <0.01
TVR, clinically driven 60 (6.7) 97 (10.7) 0.62 0.46 0.85 <0.01
Percutaneous 48 (5.4) 77 (8.5) 0.63 0.44 0.89 <0.01
Surgical 12 (1.3) 24 (2.7) 0.50 0.25 1.00 0.05
TVR, any 66 (7.4) 103 (11.4) 0.65 0.48 0.87 <0.01
Percutaneous 54 (6.0) 83 (9.2) 0.66 0.47 0.91 0.01
Surgical 12 (1.3) 24 (2.7) 0.50 0.25 1.00 0.05
TLR, clinically driven 45 (5.0) 75 (8.3) 0.60 0.42 0.86 0.01
Percutaneous 36 (4.0) 59 (6.5) 0.61 0.41 0.92 0.02
Surgical 9 (1.0) 19 (2.1) 0.48 0.22 1.05 0.06
TLR, any 56 (6.2) 86 (9.5) 0.66 0.47 0.91 <0.01
Percutaneous 47 (5.2) 70 (7.8) 0.68 0.47 0.97 0.03
Surgical 9 (1.0) 19 (2.1) 0.48 0.22 1.05 0.06
Non-TVR 74 (8.2) 70 (7.8) 1.06 0.78 1.46 0.70
Primary endpoint 165 (18.4) 227 (25.1) 0.73 0.61 0.87 <0.01
Secondary endpoint 112 (12.5) 164 (18.2) 0.69 0.55 0.86 <0.01
Target lesion failure 102 (11.4) 144 (15.9) 0.71 0.56 0.90 <0.01
Target vessel failure 113 (12.6) 161 (17.8) 0.71 0.57 0.88 <0.01
ST, deﬁnite and probable 28 (3.12) 53 (5.9) 0.53 0.34 0.83 <0.01
Early ST 2 (0.2) 15 (1.7) 0.13 0.03 0.59 <0.01
Late ST 3 (0.3) 8 (0.9) 0.38 0.10 1.42 0.13
Very late ST 23 (2.6) 31 (3.4) 0.75 0.44 1.27 0.28
Deﬁnite ST 20 (2.2) 36 (4.0) 0.56 0.33 0.96 0.03
Values are n (%) except as noted.
EES ¼ everolimus-eluting stent; PES ¼ paclitaxel-eluting stent; MI ¼ myocardial infarction; RR ¼ relative risk;
ST ¼ stent thrombosis; TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization.RESULTS
PATIENTS AND PROCEDURES. Between February
2007 and September 2008, we enrolled 1,800 patients
of whom 897 patients were randomized to EES and
903 patients to PES. Baseline patient and lesion
characteristics between EES and PES groups were
well matched (Table 1). No signiﬁcant differences in
DAPT adherence between groups was observed at 1, 6,
12, 24, 36, and 60 months follow-up (respectively for
EES: 91%, 91%, 70%, 11%, 13%, and 12%, for PES: 92%,
91%, 70%, 15%, 14%, and 12%) with the exception at
2 years (15% for PES vs. 11% for EES, p ¼ 0.02). Follow-
up at 5 years was completed in 1,791 (99.5%)
comprising 892 patients assigned to EES and 899
assigned to PES (Figure 1).
CLINICAL OUTCOMES. The clinical outcomes at
5 years are presented in Table 2. The primary
endpoint (death, MI, TVR) was signiﬁcantly lower in
patients treated with EES compared with PES (18.4%
vs. 25.1%, p ¼ 0.001), which was mainly driven by
lower rates of MI and TVR in the EES group (7.0% vs.
11.5%, p ¼ 0.001, and 7.4% vs. 11.4%, p ¼ 0.003,
respectively). All-cause mortality did not differ be-
tween groups (9.0% vs. 10.3%, p ¼ 0.36). The hazard
curves of the primary endpoint seem to diverge over
the complete follow-up period, whereas the hazard
curves for the individual endpoints MI and TVR seem
to progress in a parallel manner after 3 and 2 years,
respectively (Figure 2).
FIGURE 2 Kaplan-Meier Cumulative Event Curves for the Primary Endpoint
Kaplan-Meier cumulative event curves for the primary endpoint (A), all-cause death (B), myocardial infarction (C), and target vessel revascularization (D). At the
bottom of each graph is a table with the number at risk. Red lines indicate paclitaxel-eluting stent (PES). Blue lines indicate everolimus-eluting stent (EES).
f/u ¼ follow-up; PLR ¼ p value according to the log-rank test.
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1160The device-oriented secondary endpoint (cardiac
death, MI, clinically driven TLR) at 5 years occurred in
12.5% of patients treated with EES and 18.2% treated
with PES (p¼ 0.0008), driven by reduced rates ofMI and
clinically driven TLR (5.0% vs. 8.3%, p ¼ 0.005) in the
EES group without a signiﬁcant difference in cardiac
mortality between groups (4.5% vs. 4.7%, p ¼ 0.85).
The Academic Research Consortium deﬁnite or
probable ST rate was signiﬁcantly lower in the EES
group (3.1% vs. 5.9%, p ¼ 0.005), driven by a signiﬁ-
cant reduction in early ST (0.2% vs. 1.7%, p ¼ 0.002)
(Table 2). Rates of Academic Research Consortium
late and very late deﬁnite or probable ST were
numerically, but not statistically, lower in the EES
group (0.5% vs. 0.9%, p ¼ 0.25, and 2.6% vs. 3.4%, p ¼
0.28, respectively).In the 1-year landmark analysis, the primary
endpoint was reached by fewer patients in the EES
group compared with patients treated with PES
(12.9% vs. 17.4%, p ¼ 0.011) (Table 3). However, the
rates of the individual endpoints all-cause death
(7.2% vs. 8.8%, p ¼ 0.22), MI (4.4% vs. 6.4%, p ¼ 0.07),
TVR (5.0% vs. 5.8%, p ¼ 0.52), and deﬁnite or
probable ST (2.5% vs. 3.4%, p ¼ 0.26) were numer-
ically lower in the EES group without reaching
signiﬁcance in the 1- to 5-year follow-up period
(Figure 3).
The 5-year reduction in the primary endpoint with
EES compared with PES was consistent in all tested
subgroups. There was no signiﬁcant interaction
between treatment assignment and analyzed sub-
groups present, although there were borderline
TABLE 3 Outcome Differences Between 1 Year and 5 Years
Outcome
Patients With Events
Between 1 and 5 Yrs
Who Were Event-Free
at 1 Yr
RR
(EES/PES) 95% CI p ValueEES PES
Primary
endpoint
12.9 (108) 17.4 (142) 0.74 0.59–0.93 0.01
Death 7.2 (63) 8.8 (78) 0.82 0.59–1.12 0.22
Cardiac death 3.3 (29) 3.6 (32) 0.92 0.56–1.50 0.80
MI 4.4 (38) 6.4 (55) 0.68 0.45–1.01 0.07
Death and MI 10.4 (89) 14.2 (119) 0.73 0.57–0.95 0.02
TVR, all 5.0 (44) 5.8 (49) 0.87 0.59–1.29 0.52
TVR, clinically
driven
4.6 (40) 5.4 (46) 0.84 0.56–1.28 0.44
TLR, all 4.4 (39) 4.6 (39) 0.97 0.63–1.50 0.91
TLR, clinically
driven
3.5 (31) 3.8 (33) 0.92 0.57–1.48 0.80
TLF 7.3 (62) 8.9 (74) 0.82 0.59–1.13 0.25
TVF 7.9 (67) 10.5 (86) 0.76 0.56–1.03 0.09
ST, deﬁnite and
probable
2.5 (22) 3.4 (30) 0.72 0.42–1.25 0.26
ST, deﬁnite 1.8 (16) 2.0 (18) 0.88 0.45–1.72 0.73
Values are n (%) except as noted.
CI ¼ conﬁdence interval; TLF ¼ target lesion failure; TVF ¼ target vessel failure;
other abbreviations as in Table 2.
FIGURE 3 Kaplan-Meier Cumulative Event Curves for ST
Kaplan-Meier curve cumulative event curves for deﬁnite and probable stent thrombosis
(ST) during complete follow-up (A); and deﬁnite and probable ST after 1-year
landmark analysis (B). Probable and deﬁnite ST as deﬁned by the Academic Research
Consortium. Red lines indicate PES. Blue lines indicate EES. Abbreviations as in Figure 2.
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1161interactions in patients treated for multivessel dis-
ease or female sex (Figure 4).
DISCUSSION
This ﬁnal 5-year report from the COMPARE trial rep-
resents the largest study comparing EES to PES in an
all-comers cohort with the longest follow-up to date.
The results conﬁrm the sustained clinical beneﬁt of
EES over PES at 5 years with a 27% relative risk
reduction (RRR) in the composite primary endpoint.
This risk reduction was mainly driven by fewer TVRs
and MI in the EES group. The magnitude of risk
reduction in the EES group with regard to the primary
endpoint is similar to the previously reported risk
reduction of 29% of the endpoint target vessel failure
documented in the 3-year pooled analysis of the
SPIRIT (A Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System) II, SPIRIT
III, and SPIRIT IV trials (6).
Treatment with EES led to a 39% risk reduction of
the safety endpoint MI at 5 years, with differences
between groups most apparent during the ﬁrst 2 years
of follow-up. During the ﬁrst 30 days, the reduction of
MI might partly reﬂect the observed lower rate of
early ST in the EES group. Additionally, differences in
stent and polymer design leading to less side branch
compromise and better stent apposition with EES
might further contribute to the observed lower 30-day MI rate (5). Nevertheless, the hazard curves for
MI continue to diverge beyond 30 days and up to 3
years, which suggests that additional factors, such as
a better biocompatibility and antithrombotic proper-
ties of the ﬂuoropolymer in EES, may contribute to
this observed reduction in late MI.
Interestingly, TVR hazard curves diverge up to
2 years, which might reﬂect the better overall anti-
proliferative proﬁle of EES. However, the hazard
curves for TVR and deﬁnite and probable ST seem to
FIGURE 4 Post-Hoc Subgroup Analysis
Results of a post-hoc subgroup analysis performed with 9 clinical or angiographic variables. ACS ¼ acute coronary syndrome; LAD ¼ left anterior descending coronary
artery; MI ¼ myocardial infarction; RVD ¼ reference vessel diameter.
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1162converge slightly between 4- and 5-year follow-up.
Whether this resembles a play of chance or has a
pathophysiological cause indicating a catch-up of
neoatherosclerosis in the EES group at very late
follow-up remains unknown (12–14).
The overall deﬁnite and probable ST rate remained
signiﬁcantly lower in the EES group comparedwith the
PES group at 5 years with a RRR of 47%. As previously
reported, the rates of early ST were signiﬁcantly lower
in the EES group (RRR: 87%). The rate of late ST was
numerically lower in the EES group without reaching
statistical signiﬁcance (RRR: 50%). The 5-year follow-
up demonstrates that the very late ST rate was
numerically lower, but not signiﬁcantly different, in
the EES group compared with PES, with an overall risk
reduction of 25%. In contrast to the recently published
4-year results from the PROTECT trial (Randomized
Study Comparing Endeavor With Cypher Stents) (7),
we observed a consistently lower ST rate with EES
throughout the 5-year follow-up, though in the 1-yearlandmark analysis, the ST curves seem to converge
between 4- and 5-year follow-up (Figure 3B). Whether
this observation is true and consistent beyond 5 years
remains uncertain because of the modest sample size
of the study and the fact that follow-upwas limited to 5
years. However, our results emphasize again the
importance of long-term follow-up of randomized
controlled trials in DES.
Because groups were well matched with regard to
patient, lesion, and procedure characteristics, the
observed effects are most likely due to the speciﬁc
features of the EES system compared with PES. It has
been speculated that differences in the stent platform
including metallic platform (material, geometry,
strut thickness, deliverability), polymer (composition,
thickness, biocompatibility, thrombogenicity, proin-
ﬂammatory potential), and antiproliferative drug
(molecular composition, biological actions, doses,
release kinetics) might all contribute to the observed
differences between the devices. Moreover, more
TABLE 4 Patient Characteristics With EES and Deﬁnite Or Probable Very Late ST
Patient #
Event Data Index Data
Def/Prob
ST
Event
Type
Days After
Index P2Y12 Type On DAPT
Antithrombotic
Agent
Age
(yrs) Sex DM Smoking*
Index
Procedure Vessel
Lesion
Type
Total Stent
Length Post-Dilation
Bif
Treatment
Vessel
Disease
0015 Prob NSTEMI 1,405 Clop No Clop 60 F 2, NIDDM Yes/yes STEMI RCX B2 18 Yes Yes 2
0353 Def STEMI 933 No No ASA 55 M 2, NIDDM Yes/yes STEMI RCA B1 23 No No 2
0555 Def STEMI 871 No No ASA 53 M No No STEMI RCA C 28 No Yes 3
0593 Def NSTEMI 1,134 No No ASA 34 F No Yes/yes STEMI LAD C† 92 Yes No 2
0650 Def NSTEMI 380 No No ASA 62 F No Ex NSTEMI RCA C† 46 No No 2
0736 Prob NSTEMI 1,410 No No ASAþOAC 69 F 2, NIDDM Ex SAP RCX C 58 No No 2
0738 Def STEMI 854 No No ASAþOAC 68 M No Yes/yes NSTEMI LAD B1† 12 No No 1
0773 Def NSTEMI 1,241 Clop Yes ASAþClop 48 M 2, NIDDM Ex UAP LAD C 97 Yes Yes 1
0803 Def STEMI 711 Clop Yes ASAþClop 56 M No Yes/yes STEMI RCX C‡ 64 Yes Yes 3
0808 Prob NSTEMI 544 Clop Yes ASAþClop 74 M 2, IDDM Yes/yes NSTEMI Graft C 54 No No 3
0831 Def Dyspnea 1,393 N No ASAþOAC 68 F No Ex SAP RCX B2† 36 No No 3
0883 Def STEMI 1,516 N No ASA 55 M No Yes/yes STEMI LAD B2 33 Yes Yes 1
0965 Prob NSTEMI 1,599 Clop Yes ASAþClop 64 F No Yes/ukn NSTEMI LAD B1 23 Yes No 1
1083 Def STEMI 1,647 N No ASA 57 M No Yes/no SAP RCA B1 43 Yes No 3
1231 Def STEMI 1,249 N No N 75 M No No SAP RCA B2 56 Yes No 2
1288 Def NSTEMI 1,554 Clop Yes ASAþClop 57 M 2, IDDM Ex NSTEMI Graft C 28 Yes No 3
1318 Prob NSTEMI 1,669 N No ASA 78 M No Ex SAP RCA B1 28 Yes No 3
1331 Prob Death 1,469 N No ASA 72 M No Ex SAP LAD C§ 59 Yes Yes 3
1406 Prob NSTEMI 1,638 Y Yes ASAþDipyr 50 M No Yes/yes SAP LAD B2 40 No No 3
1452 Def STEMI 1,449 Ukn Ukn Ukn 60 M No Yes/yes NSTEMI LAD B2 40 Yes No 1
1484 Def STEMI 1,317 N No ASA 75 F 2, NIDDM No SAP LAD C§ 48 Yes No 2
1514 Def STEMI 571 N No ASA 48 M No No STEMI RCA B2 15 No No 3
1728 Def STEMI 1,477 N No ASA 57 M No Yes/yes SAP LAD B1 15 Yes Yes 2
*Active smoking at index or at event. †Index lesion in-stent thrombosis or restenosis of Cypher stent. ‡Index procedure in-stent thrombosis of bare-metal stent. §Index lesion very calciﬁed and rotablator procedure.
ASA ¼ acetylsalicylic acid; Bif ¼ bifurcation; Clop ¼ clopidogrel; DAPT ¼ dual antiplatelet therapy; Def ¼ deﬁnite; Dipyr ¼ dipyidamole; DM ¼ diabetes mellitus; Ex ¼ ex-smoker; F ¼ female; IDDM ¼ insulin-dependent diabetes mellitus; LAD ¼ left anterior coronary
artery; M ¼male; NIDDM ¼ non–insulin-dependent diabetes mellitus; NSTEMI ¼ non–ST-segment elevation myocardial infarction; OAC ¼ oral anticoagulant (vitamin K antagonist); Prob ¼ probable; RCA ¼ right coronary artery; RCX ¼ circumﬂex coronary artery; SAP ¼
stable angina pectoris; STEMI ¼ ST-segment elevation myocardial infarction; UAP ¼ unstable angina pectoris; Ukn ¼ unknown; other abbreviations as in Table 2.
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1164rapid re-endothelialization with EES as documented
in animal models might contribute to the present
ﬁndings because it has been shown that incomplete
endothelialization is strongly associated with the risk
of ST (15,16). The average annual increment of very
late ST between 1 and 5 years was 0.64% in the EES
and 0.86% in the PES group. Both very late ST rates
are higher when compared with the previously re-
ported very late ST rates in the 5-year SPIRIT III
trial paper (average annual increment of 0.12% for
EES and 0.25% for PES) and the 3-year pooled
analysis of the SPIRIT trials (average annual incre-
ment of 0.18% for EES and 0.34% for PES) and
various meta-analyses (6,17,18). The observed dif-
ferences might be explained by the all-comers
design of the present study thus including higher-
risk patient and lesion characteristics. In fact, only
5 of the 23 very-late ST cases within the COMPARE
study would have fulﬁlled the inclusion and
exclusion criteria for enrollment in the SPIRIT trials.
Second, in the COMPARE trial, DAPT was stopped
after 1 year in 89% to 85% of the patients, whereas
in the SPIRIT III trial, DAPT discontinuation after
1 year was about 28% to 29% (19). However, both
the SPIRIT and COMPARE trials were underpowered
to evaluate differences in ST between the stent
platforms. Only in a pooled analysis of the SPIRIT
II, III, and IV and COMPARE trials of 6,789 patients
with follow-up at 2 years, we could identify that
interruption of DAPT beyond 6 months after im-
plantation of EES was safe, whereas the opposite
was true for PES (20). Detailed information on pa-
tient and lesion characteristics and DAPT usage of
patients with very-late ST in the EES group up to
5 years follow-up is given in Table 4.
The relative beneﬁts of EES compared with PES in
reducing the primary endpoint were consistent across
all analyzed subgroups. However, interaction testing
was nonsigniﬁcant between stent type and analyzed
subgroups. Of note, there was a trend for greater ab-
solute beneﬁt in female patients and in patients with
multivessel treatment (p for interaction ¼ 0.05 and
0.08, respectively). The former ﬁnding potentially
reﬂects the superiority of EES over PES in smaller
vessels and more complex lesions, which are more
prevalent in the female PCI population compared with
the male PCI population. The latter ﬁnding, combined
with the overall superiority of EES over PES at 5-year
follow-up in this trial, raises the possibility that the
SYNTAX (TAXUS Drug-Eluting Stent Versus Coronary
Artery Bypass Surgery for the Treatment of Narrowed
Arteries) trial might have been more favorable for PCI
if EES had been used as the comparator to coronary
artery bypass graft surgery (21,22).Finally, the SPIRIT III and SPIRIT IV trials, as well
as pooled patient-level analysis consisting of the
SPIRIT II, SPIRIT III, SPIRIT IV, and COMPARE trials,
have suggested a diminished efﬁcacy of EES com-
pared with PES measured by the endpoint target
lesion failure in the diabetic subgroup (4,5,23). How-
ever, our stratiﬁed analysis shows numerical superior
performance of EES compared with PES in patients
with diabetes at 5-year follow-up. Additional studies
are warranted to delineate the interaction between
diabetic state, DES, and vascular response.
STUDY LIMITATIONS. The COMPARE trial was con-
ducted in a single high-volume, tertiary center, and
the results might not be applicable in other settings.
Furthermore, PES is now seldom used in clinical
practice, and these results may have limited rele-
vance, though long-term data are imperative for
conﬁrmation of initial results because some other
comparative stent trials reported signiﬁcant changes
in outcomes over different study time points. Sec-
ondly, the study was underpowered to derive reliable
estimates of relatively low-frequency adverse events
such as death or ST. Similarly, subgroup analysis is
inherently underpowered and should be considered
hypothesis generating. Thirdly, we report on a sec-
ondary endpoint, and testing of the primary endpoint
at multiple time points other than the speciﬁed 1-year
primary endpoint is subject to the perils of multiple
testing. Finally, the standard antiplatelet regimen
after DES implantation at the time of the study was
aspirin and clopidogrel for 12 months. A possible
impact on the study results of a longer duration of
DAPT or the use of the recent more potent P2Y12 re-
ceptor inhibitors, such as of prasugrel or ticagrelor,
remains unknown.
CONCLUSIONS
At 5 years, treatment with EES compared with PES
resulted in sustained clinical beneﬁts. The separation
of the hazard curves for TVR, MI, and ST occurred in
the ﬁrst 2 to 3 years. With progression of time, the
curves start to run parallel.
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PERSPECTIVES
WHAT IS KNOWN? Long-term data of comparative DES
trials are scarce.
WHAT IS NEW? This paper reports that with a follow-
up of 5 years, the everolimus-eluting XIENCE stent
remains superior in outcome compared with the
paclitaxel-eluting TAXUS stent.
WHAT IS NEXT? It also shows an ongoing device-
related event rate, which indicates the need for new stent
or resorbable scaffold technology to further improve
outcome of patients with coronary artery disease treated
with PCI.
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